GlassScriptPhysician profile
Luis M Barcena Blanch
NPI 1144484346
$3,274.58
in general payments reported to CMS, 2019-2025
13 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 81% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.22 · 2020: $50.25 · 2021: $41.80 · 2022: $249 · 2023: $510 · 2024: $1,141 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,869 · Education: $27.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,869.33 |
| Education | $27.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $581.84 | 2023-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $526.76 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Viiv Healthcare Company | $423.38 | 2023-2025 | Dovato, Cabenuva, Apretude |
| Abbvie INC. | $395.45 | 2022-2025 | Avycaz, Dalvance, Teflaro |
| Glaxosmithkline, LLC. | $368.22 | 2022-2024 | Trelegy Ellipta |
| Melinta Therapeutics, LLC | $269.62 | 2020-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Paratek Pharmaceuticals, INC. | $255.47 | 2023-2025 | Nuzyra |
| Insmed, INC. | $189.47 | 2023-2025 | Arikayce, Brinsupri |
| Cumberland Pharmaceuticals, INC. | $104.72 | 2025 | Vibativ |
| Aimmune Therapeutics, INC. | $89.81 | 2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $35.66 | 2024 | Rebyota |
| Smith+Nephew, INC. | $17.73 | 2024 | Collagenase Santyl |
| La Jolla Pharmaceutical Company | $16.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Barcena Blanch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.